Form 8-K - Current report:
SEC Accession No. 0001193125-25-015683
Filing Date
2025-01-29
Accepted
2025-01-29 16:21:17
Documents
14
Period of Report
2025-01-26
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d64200d8k.htm   iXBRL 8-K 29264
  Complete submission text file 0001193125-25-015683.txt   187798

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA dvax-20250126.xsd EX-101.SCH 3877
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dvax-20250126_def.xml EX-101.DEF 13673
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dvax-20250126_lab.xml EX-101.LAB 22622
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dvax-20250126_pre.xml EX-101.PRE 14641
17 EXTRACTED XBRL INSTANCE DOCUMENT d64200d8k_htm.xml XML 5486
Mailing Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 25569649
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)